Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus MICONAZOLE NITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus MICONAZOLE NITRATE.
GRIS-PEG vs MICONAZOLE NITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
Inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
Topical: Apply twice daily for 2-4 weeks. Vaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 1200 mg suppository as a single dose. Oral (buccal): 50 mg once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Terminal elimination half-life is approximately 24 hours (range 20-40 hours) following intravenous administration. This extended half-life supports twice-daily dosing for systemic infections.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Miconazole is primarily metabolized in the liver, with less than 1% of an intravenous dose excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of the dose as metabolites. Renal elimination of metabolites is minimal.
Category C
Category A/B
Antifungal
Antifungal